How Robotic Process Automation and AI Can Speed Drugs to Market

Robotic Process Automation (RPA) can cut time and headaches to speed drugs to market.

RPA is an emerging form of business process automation technology based on the notion of software robots (bots) that let any business user train a bot. These bots can then go out and complete boring, time-consuming, repetitive backend processes for companies. For most companies, this means that humans will be freed from filling out purchase orders, W-2s, and other business-critical items.

With life sciences companies and universities where clinical trials are taking place, automation and, specifically RPA should be a top priority.

Improved productivity would be a real boon to the clinical trials. Clinical trial processes are resource intensive and rely heavily on highly trained scientists and doctors at virtually every step. The cost of bringing a single drug to market is anywhere from $1.5–2.5 billion¹ and these costs continue to rise.

Here’s a relatively easy step to reduce the cost, time, and headache of clinical trials.

Much of the work in the trials by trained Ph.D.’s completing repetitive, low-level tasks: generating first tasks of documents like protocols, data management plans, and statistical analysis plans. In addition, these rote activity…